Yahoo Finance14d
Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU
Basel, 31 January 2025 - Roche ... PATHWAY HER2 (4B5) test was used as part of the DESTINY-Breast06 trial, which showed a median progression-free survival of 13.2 months with ENHERTU compared to 8 ...
Taiwan News14d
Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU
Basel, 31 January 2025 - Roche (SIX ... tissue samples. The PATHWAY HER2 (4B5) test was used as part of the DESTINY-Breast06 trial, which showed a median progression-free survival of 13.2 months with ...
Yahoo Finance14d
Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU
With the introduction of HER2-low and now HER2-ultralow classifications, Roche ... PATHWAY HER2 (4B5) test was used as part of the DESTINY-Breast06 trial, which showed a median progression-free ...
Seeking Alpha15d
Roche Holding AG (RHHBY) Q4 2024 Earnings Call Transcript
[Operator Instructions] One last remark, if you would like to follow the presented slides on your end as well, please feel free to go to ... CHF1.1 billion more taxes than last year. Part of ...
EuropaWire14d
Roche Expands FDA Approval of PATHWAY® HER2 Test for HER2-Ultralow Breast Cancer Status
(PRESS RELEASE) BASEL, 1-Feb-2025 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced that the U.S. Food and Drug Administration (FDA) has granted an expanded label for its PATHWAY® anti ...
The Victoria Advocate17d
Roche receives FDA 510(k) clearance for the first blood test in the U.S. measuring Lp(a) in molar units
1 The Roche Diagnostics Tina-quant® Lipoprotein ... For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution ...
eLife10d
Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab resistant HER2 positive breast cancer
This study presents a useful finding that targeting amino acid metabolism can overcome Trastuzumab resistance in HER2+ breast cancer. The evidence supporting the claims of the authors is solid and the ...
News Medical on MSN4d
GUK1 enzyme plays crucial role in lung cancer metabolism and growth
Lung cancer is a particularly challenging form of cancer. It often strikes unexpectedly and aggressively with little warning, and it can shapeshift in unpredictable ways to evade treatment.